- Motley Fool•13 hours ago
Has the market overestimated the odds of success for Tesaro's fancy new cancer drug?
- Reuters•20 hours ago
AstraZeneca's move to the English university city of Cambridge will cost more and take longer than initially expected, following increased expenditure on new technology and equipment. Investment in Cambridge, where AstraZeneca is building a strategic R&D centre and global corporate headquarters, is now expected to be more than 500 million pounds ($640 million), the drugmaker said on Tuesday. For Chief Executive Pascal Soriot, the new site on the Cambridge Biomedical Campus symbolizes his desire to create a science-led company with uniquely close ties to academia.
- Investopedia•5 days ago
A look at Tesaro's recent decline and the bearish head and shoulders pattern emerging in its chart.
AZN : Summary for Astrazeneca PLC Common Stock - Yahoo Finance
AstraZeneca PLC (AZN)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||30.47 - 30.63|
|52 Week Range||25.55 - 35.04|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||22.09|
|Dividend & Yield||1.90 (6.30%)|
|1y Target Est||N/A|